Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer Patients Treated in Clinical Practice

Rossi, Luigi; Veltri, Enzo; Zullo, Angelo; Zoratto, Federica; Colonna, Maria Antonietta; Seri, M. Di; Longo, Flavia; Mottolese, Marcella; Giannarelli, Diana; Ruco, Luigi; Romiti, Adriana; Barucca, Viola; Adua, Daniela; Tomao, Silverio

doi:10.2217/fon.12.108

Cited by 5 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a different study, Rossi et al determined that colorectal cancer patients with only hepatic metastases responded better to combined chemotherapy and bevacizumab treatment than patients with extrahepatic metastases or multiple metastases. They also determined that 41.7% of patients had stable disease, 39.8% had partial response to treatment, 3.7% had a complete response to treatment and 14.8% had progressive disease [16]. The results of our study were similar to their study, with 31.8% of patients responded to treatment, while 68.2% of patients did not respond to the treatment.…”

Section: Lubezky Et Al Evaluated Fdg-pet and Ct's Effectiveness And supporting

confidence: 85%

Evaluation of the Effectiveness of Bevacizumab Treatment in Patients with Metastatic Colorectal Cancer with PET-CT

Çerçi¹

2016

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

Purpose: To evaluate the response to therapy with PET-CT in metastatic colorectal cancer patients treated with Bevacizumab and chemotherapy.Methods: Twenty-two patients with metastatic colorectal cancer that were treated with bevacizumab and 6 cycles of chemotherapy were evaluated by whole-body PET-CT scan before and after the treatment in accordance with the European Organization for Research and Treatment of Cancer criteria.Results: While 31.8% of patients responded to treatment (complete response + partial response), 68.2% did not respond to treatment (stable disease + progressive disease). The mean hepatic, extra hepatic, abdomen, lung and bone metastases SUVmax values were higher after treatment in comparison to the pre-treatment values. There was an increase in SUVmax values in those who did not respond to the treatment, while a decrease was observed in those who responded to the treatment. Survival was significantly increased in all patients that responded to the treatment. The difference in terms of gender, histological subtype, histological grade, primary tumor location, presence of metastases in regional lymph nodes and liver at the time of diagnosis or the response to the treatment was not statistically significant. Conclusions:In this study we detected metabolic response before anatomical response with PET-CT in one third of metastatic colorectal cancer patients treated with Bevacizumab and chemotherapy. This finding suggests that PET-CT may be used as a measure to follow therapy response and predict the prognosis in metastatic colorectal cancer patients.

show abstract

Section: Lubezky Et Al Evaluated Fdg-pet and Ct's Effectiveness And supporting

confidence: 85%

Evaluation of the Effectiveness of Bevacizumab Treatment in Patients with Metastatic Colorectal Cancer with PET-CT

Çerçi¹

2016

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

show abstract

“…Response rates to treatment with bevacizumab according to K-ras expression have been reported in our previous retrospective study 26. Survival results were last updated in March 2012.…”

Section: Methodsmentioning

confidence: 93%

“…The design of this study has been reported previously 26. In brief, this was a retrospective study enrolling consecutive 108 unresectable mCRC patients, treated in clinical practice in three Italian oncology centers (Rome, Latina, Gaeta) between September 2008 and March 2011.…”

Section: Methodsmentioning

confidence: 99%

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation

Rossi¹,

Veltri²,

Zullo³

et al. 2013

OTT

Self Cite

View full text Add to dashboard Cite

BackgroundBevacizumab plus chemotherapy prolongs progression-free survival (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC). Although there is strong evidence to suggest that the mutational status of the K-ras oncogene has a role as a predictive factor for activity in patients treated with cetuximab and panitumumab, few data have been obtained in patients treated with bevacizumab. We conducted an additional retrospective analysis to investigate the prognostic value of K-ras mutation relative to mCRC first-line treatment with bevacizumab.Materials and methodsA total of 108 patients were retrospectively reviewed. K-ras status was assessed in the overall population by sequencing. Statistical association for PFS and OS was analyzed using the Kaplan–Meier method, and the prognostic role of K-ras was determined using the logrank test.ResultsMedian PFS was 10 months both for patients with wild-type (WT) K-ras and mutated (MT) K-ras (hazard ratio [HR] 0.94, P=0.75); neither difference in median OS was significant (27 months WT K-ras versus 26 months MT K-ras, HR 0.92; P=0.70). A further analysis was carried out in the two groups according to metastatic sites. No statistically significant difference in terms of PFS and OS was demonstrated between WT K-ras and MT K-ras with liver metastases only and in those with extrahepatic disease.ConclusionAlthough further study is required, our results seem to confirm that K-ras mutation does not have a prognostic role in mCRC patients receiving first-line treatment with bevacizumab.

show abstract

“…6 The use of systemic therapy to consequently achieve resectability offers a curative option, with long-term outcomes similar to those achieved with primary resection. 36 Therefore, in the present phase II study, we assessed the efficacy of the neoadjuvant therapy combination of bevacizumab and XELOX to increase the resection rate in patients with previously untreated mCRC with liver metastases. The dosage of XELOX and bevacizumab in this trial was based on the development program for each individual drug.…”

mentioning

confidence: 99%

Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial

Chen

Lin

Chen

et al. 2017

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Aim: This phase II, open-label study evaluated the efficacy and safety of neoadjuvant therapy with bevacizumab plus XELOX (capecitabine and oxaliplatin) for untreated metastatic colorectal cancer with unresectable liver metastases and assessed conversion of unresectable to resectable metastases after neoadjuvant treatment. Methods:Patients received bevacizumab 5 mg/kg and oxaliplatin 85 mg/m 2 on day 1, and capecitabine 1000 mg/m 2 twice daily on days 1-5 followed by 2 days of rest in a 14-day cycle for 12 cycles; bevacizumab was excluded in cycles 6 and 7. Patients were later divided into resected and unresected groups, depending upon whether they underwent curative resection after chemotherapy. Efficacy and safety were evaluated.Results: Of 45 patients enrolled, 17.8% completed the study. The resection rate of liver metastases after neoadjuvant therapy was 42.2%. The median time to disease progression was 10.1 and 8.7 months in the resected and unresected groups, respectively (P = 0.1341). Response rate was significantly higher in the resected (47.4%) versus the unresected group (34.6%; P = 0.0010), and seven patients achieved complete response (resected group). Overall, 94.3% of adverse events were of mild or moderate severity, and grade ≥3 adverse events occurred in 4.3% and 7.3% of patients in the resected and unresected groups, respectively. The most common adverse events in both groups were palmar-plantar erythrodysesthesia syndrome, decreased appetite, thrombocytopenia, peripheral neuropathy, fatigue, diarrhea, vomiting, proteinuria and nausea. Conclusion:Neoadjuvant therapy with bevacizumab plus XELOX was well tolerated and effective in previously untreated metastatic colorectal cancer patients with initially unresectable liver metastases. K E Y W O R D Sbevacizumab, liver metastases, metastatic colorectal cancer, neoadjuvant therapy, XELOX

show abstract

Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer Patients Treated in Clinical Practice

Abstract: Bevacizumab plus chemotherapy provides clinical benefit and objective response rate in patients with metastatic colorectal cancer independently of KRAS expression, especially in those patients with only liver metastases.

Cited by 5 publications

References 28 publications

Evaluation of the Effectiveness of Bevacizumab Treatment in Patients with Metastatic Colorectal Cancer with PET-CT

Evaluation of the Effectiveness of Bevacizumab Treatment in Patients with Metastatic Colorectal Cancer with PET-CT

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation

Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial

Contact Info

Product

Resources

About